(NASDAQ: OKYO) Okyo Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.36%.
Okyo Pharma's earnings in 2026 is -$8,949,657.On average, 3 Wall Street analysts forecast OKYO's earnings for 2027 to be -$18,199,900, with the lowest OKYO earnings forecast at -$17,486,178, and the highest OKYO earnings forecast at -$18,735,191. On average, 3 Wall Street analysts forecast OKYO's earnings for 2028 to be -$17,129,318, with the lowest OKYO earnings forecast at -$16,457,580, and the highest OKYO earnings forecast at -$17,633,121.
In 2029, OKYO is forecast to generate -$21,065,282 in earnings, with the lowest earnings forecast at -$20,236,106 and the highest earnings forecast at -$21,684,541.